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A metaanalysis comparing surgical thrombectomy,
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thrombolysis for thrombosed dialysis grafts
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Ontario, Canada
Background: The achievement and maintenance of access sites for hemodialysis is a persistent challenge for both the
vascular surgeon and the clinical nephrologist. The advent of improved interventional, endovascular, and pharmacome-
chanical techniques for the treatment of thrombosis has raised questions as to whether surgical thrombectomy is the most
effective treatment.
Objective: The purpose of this study was to determine the role of surgical thrombectomy as the standard of care for the
patient with end-stage renal disease and a thrombosed/stenosed arteriovenous graft (AVG).
Design and methods: The study was designed as a metaanalysis. All publications that directly or indirectly described
randomized controlled trials for the treatment of thrombosed dialysis grafts in patients with end-stage renal disease and
AVG were searched. Relative risk (RR) and risk difference were used as the measure of effect for each dichotomous
outcome. All of the studies that met the inclusion criteria were limited to prosthetic AVGs.
Results: The overall results suggested a clear superiority of surgery over endovascular procedures at 30 days, 60 days, 90
days, and 1 year. The RRs (95% CI) at these time points were 1.32 (1.07, 1.60), 1.34 (1.13, 1.58), 1.22 (1.05, 1.40), and
1.22 (1.07, 140), respectively, and favored surgery in all cases (30 days, P .010; 60 days, P .0007; 90 days, P .007;
and 1 year P  .003). The number needed to treat to prevent one endovascular occlusion after thrombectomy was 8 at
30 days, 6 at 60 days, 8 at 90 days, and 7 at 1 year. The rates of technical failure were significantly greater in the
endovascular group compared with the surgical group (RR, 1.90; 95% CI, 1.32, 2.73; P  .0005), which generated an
absolute risk reduction of 16% (P .0002). No significant difference was seen in the complication rates between the two
groups.
Conclusion: The analysis of all currently available randomized controlled trials clearly supports the use of surgical
thrombectomy for the treatment of thrombosed prosthetic vascular access grafts. The use of endovascular techniques has
been found to be inferior to surgery in terms of both primary patency and technical failure rates. (J Vasc Surg 2002;36:
939-45.)
The achievement and maintenance of sites for hemodi-
alysis is a persistent challenge for both the vascular surgeon
and the nephrologist. A hemodialysis access that remains
patent and free of infection is critical to ensuring a high
standard of care for the patient with end-stage renal disease
(ESRD). An arteriovenous fistula (AVF) is the gold stan-
dard for the establishment of primary vascular access. An
AVF can be constructed either as a simple fistula (an artery
connected to a vein) or as an interposition graft (an artery
connected to a vein with prosthetic material [PAVG]). The
most common prosthetic material used in the construction
of interposition grafts is polytetrafluoroethylene. Unfortu-
nately, graft failures are frequent and contribute to multiple
hospital readmissions, complex reinterventions, invasive
radiologic studies, and the significant overall morbidity rate
associated with chronic hemodialysis. The main complica-
tions of AVFs and PAVGs are stenosis, thrombosis, pseu-
doaneurysm formation, and infection.1 That the treatment
provided to remedy the situation be highly effective with
minimal associated morbidity and mortality is imperative to
the patient with ESRD.
The most common of these complications is graft ste-
nosis and subsequent thrombosis. Indeed, 85% of all AVF
complications may be the result of thrombosis caused by
myointimal hyperplasia, especially in prosthetic grafts.2
These stenotic lesions are located at or near the site of a
venous anastomosis in 58% to 90% of patients.3 In the past,
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traditional treatment of a thrombosed AVF or PAVG con-
sisted of surgical thrombectomy followed by local revision
of the access. However, the efficacy of such repairs as
measured with primary patency (defined as the point in
time after the surgical intervention when graft failure oc-
curs before any further patency-prolonging revisional inter-
ventions) has been poor. Reported 1-year primary patency
rates have ranged from 3% to 36%.3
The advent of improved interventional, endovascular,
and pharmacomechanical techniques for the treatment of
thrombosis has raised questions as to whether surgical
thrombectomy is the most effective treatment option in
terms of both cost to healthcare and morbidity to the
patient. The potential advantage of these nonsurgical
methods is the decreased morbidity rate associated with the
procedure. However, if the patency rate is not comparable
with that of surgical techniques, then their usefulness is
limited because multiple procedures may be necessary, thus
increasing the overall morbidity to the patient. The ideal
procedure is one that is rapid, safe and effective and one
that would allow a quick return to the dialysis unit for
timely effective treatment. Furthermore, it should have a
good primary patency rate to minimize the risk and mor-
bidity associated with multiple procedures.
The objective of this analysis was to assess the effective-
ness of surgical thrombectomy as the standard of care for
the patient with ESRD and a thrombosed/stenosed arte-
riovenous graft (AVG) versus endovascular procedures (1,
mechanical thrombectomy; 2, pharmacomechanical
thrombolysis; and 3, endovascular procedures). The pri-
mary outcome was primary patency rate, and secondary
outcome measures included secondary patency, cumulative
patency, complication, and technical failure rates.
METHODS
The studies included in the review were randomized
and quasirandomized controlled trials of surgical throm-
bectomy versus: 1, mechanical thrombectomy; 2, pharma-
comechanical thrombolysis; or 3, endovascular procedures.
A quasirandomized study is defined as a trial with a quasi-
random method of allocating participants to different
forms of care. Quasirandom allocation is a method of
allocating participants to different forms of care that is not
truly random; for example, allocation by date of birth, day
of the week, medical record number, month of the year, or
the order in which participants are included in the study
(eg, alternation).
The three treatment options were combined under the
heading of endovascular procedures for the purpose of this
analysis. This grouping was because of the existing hetero-
geneity of the various endovascular procedures and the lack
of a “gold standard” endovascular technique. Patients had
to be randomly allocated to one of the two treatment
groups. All methods of randomization were eligible for
inclusion in the study, with differences in quality being
taken into account during the analysis of the study meth-
odology. Trials that failed to analyze the results on an
intention-to-treat basis were only included if no loss to
follow-up was found.
Male and female patients aged 18 to 80 years with
diagnosis of ESRD undergoing hemodialysis via AVF or
PAVG were considered. The fistula had to be constructed
from either native vein or a prosthetic interposition graft
(polytetrafluoroethylene). For the purposes of the litera-
ture search, both AVFs and PAVGs were considered and
were defined jointly as AVGs. AVGs located in the upper or
lower limbs were included. Patients undergoing peritoneal
dialysis were considered only if the creation of the AVG was
performed because of an impending transfer from perito-
neal to hemodialysis.
The primary outcome was primary patency rate as
outlined with life-table analysis or Kaplan-Meier survival
curves.4 Secondary outcome measures included secondary
patency, cumulative patency, complication, and technical
failure rates. For the purpose of this analysis, primary pa-
tency was defined as the point in time after the surgical
intervention when graft failure occurred before any further
patency-prolonging revisional interventions.
All publications that directly or indirectly described
randomized controlled trials for the treatment of throm-
bosed dialysis grafts in patients with ESRD and AVG were
sought with computerized searches of EMBASE and
MEDLINE and hand searches of relevant medical journals
as of July 2001. Additional searches of the Cochrane Con-
trolled Trials Register and reference lists were made. No
restrictions of language or date of publication were made.
The methodologic quality of included trials was as-
sessed independently by the three reviewers, with any dis-
crepancies resolved by group discussion and consensus.
Quality was assessed with a data abstraction form that was
designed for this specific research question. Specific quality
scales that were incorporated into the abstraction form
included: the Jadad Score,5 the Schulz Scale,6 and the
assessment criteria widely used by the Cochrane Collabo-
rative Review Group.7 An important note is that because
one of the treatment arms involved a surgical intervention,
blinding was not possible. The abstraction form also was
used to explore possible heterogeneity of the methods and
quality of the various studies.
Relative risk (RR) was used as the measure of effect for
each dichotomous outcome. Primary patency rate was
transformed into a dichotomous outcome for specific time
periods (30 days, 60 days, 90 days, and 1 year). The grafts
were assessed to be either patent or thrombosed at the end
of each time period. Where sufficient data were found, a
summary statistic for each outcome was calculated with
both a fixed-effects and a random-effects model (if hetero-
geneity was present). The heterogeneity of the data was
assessed and addressed in terms of a generic inferential
framework. A P value of less than .10 was considered to
represent significant heterogeneity. Sensitivity analyses
were undertaken to examine the stability of the results.
Where continuous scales of measurement were used to
assess the effects of treatment, these data were analyzed in a
continuous form (ie, weighted mean difference). If differ-
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ent scales were used in different studies, where possible, the
results were standardized and then combined (ie, standard-
ized mean differences). All statistical analysis was done with
the Revman 4.1 software (Cochrane Collaboration, Ox-
ford, UK).
RESULTS
Nine studies were identified as possible candidates for
this systematic review. From this total, seven studies met
inclusion criteria. These studies included a total of 479
patients with thrombosed dialysis grafts necessitating ther-
apeutic intervention. In total, four articles originated from
surgical journals and three were obtained from the inter-
ventional radiology literature. Two studies were excluded
from the analysis. The study by Beathard8 lacked a surgical
control arm and did not fulfill the objective of comparison
of surgery with endovascular procedures. The study by
Schwartz et al9 was not a randomized or quasirandomized
controlled trial. The Methods section clearly describes a
prospective study with a historical control group.
The patient demographics were similar across all stud-
ies. Significant variability was seen in the definition and
reporting of primary patency across the included studies.
Follow-up was complete in all studies. This was not surpris-
ing because all patients were hemodialysis dependent and
needed multiple hospital visits each week. All analyses were
reported as intention-to-treat. Because of the surgical na-
ture of the intervention, blinding of both the intervention
and the outcome was not possible. Inclusion and exclusion
criteria for all studies were similar, ensuring the homoge-
neity of patients for comparison. An important note is that
all of the grafts in the studies that met the inclusion criteria
were PAVGs.
The convention when reporting the efficacy of these
procedures is to use patency as the outcome measure.
However, with analysis of the data, we entered the number
of outcome events (n) as the number of thrombosed grafts.
Therefore, a higher number of outcomes (n) refers to a
larger number of thrombosed grafts and, therefore, to
decreased patency. For example, in Marston et al,10 the
30-day primary patency rate results for the endovascular
arm were reported as 33/59 (n/N). This would translate
into 33 thrombosed grafts, which is equal to a thrombosis
rate of 56%. However, by convention, we would report this
as a primary patency rate of 44%.
The overall results of the metaanalysis showed a clear
superiority of surgery over endovascular procedures at 30
days, 60 days, 90 days, and 1 year. The RRs (95% CI) at
these time points were 1.31 (1.07, 1.60), 1.34 (1.13,
1.58), 1.22 (1.05, 1.40), and 1.22 (1.07, 140), respec-
tively, and favored surgery in all cases (30 days, P  .010;
60 days, P  .0007; 90 days, P  .007; and 1 year, P 
.003). The studies with the largest weights were Marston et
al10 and Vesely et al.11 All results were found to be homog-
enous, with the test for heterogeneity having a P value of
more than .10 (range, .17 to .84) in all cases (Fig 1).
The risk difference (RD; 95% CI) also favored surgery
over endovascular procedures at 30 days, 60 days, 90 days,
and 1 year. The results at these respective time points were
0.14 (0.04, 0.25), 0.18 (0.08, 0.27), 0.14 (0.04, 0.23),
and 0.16 (0.06, 0.26). These results were significant in all
cases (30 days, P .008; 60 days, P .0004; 90 days, P
.006; and 1 year, P  .002). The number needed to treat
(NNT) with surgical thrombectomy to avoid an endovas-
cular thrombosis was 8 at 30 days, 6 at 60 days, 8 at 90 days,
and 7 at 1 year (Fig 2). The NNT can be calculated as
1/RD. For the purposes of the analysis, NNT was calcu-
lated with the total RD, which incorporated data from all
included studies.
The rates of technical failure were significantly greater
in the endovascular group as compared with the surgical
group (RR, 1.90; 95% CI, 1.32, 2.73; P  .0005), which
generated a RD (95% CI) of 0.16 (0.07, 0.24; P .0002),
with the NNT with surgical thrombectomy to avoid an
endovascular technical failure being 7 (Fig 3). No signifi-
cant difference was seen in complication rates between the
two groups.
The results of a sensitivity analysis of 30-day primary
patency rate and the RR, 95% CI, P values for the test of
heterogeneity, and P values for overall effect are listed in
Table I. This analysis showed the robustness of the results.
All results remained significant except for the case when the
Marston et al10 study was removed. In that instance, the P
value rose to .06 and the CI did cross unity (0.99, 1.59),
showing borderline significance. Of note, all results re-
mained significant and CIs did not cross unity regardless of
which study was removed in the sensitivity analysis of 1-year
primary patency rate (Table II). The results of this second
sensitivity analysis showed the robustness of the results with
a highly significant overall effect in all cases. These results
mirrored the trend that developed with primary analysis of
the data. Finally, a sensitivity analysis of technical failure
rates showed that the decrease in technical failures with the
surgical approach was robust in the sensitivity analysis.
DISCUSSION
The results of this systematic review show that surgical
thrombectomy remains the gold standard for the treatment
of thrombosed prosthetic vascular access grafts. The
strength of these results may have been even greater if a
more thorough reporting of long-term patency results ex-
isted in the literature. To date, only three studies3,10,12
presented data for 1-year primary patency results.
The most surprising result was that surgery was supe-
rior at the shorter time interval outcomes (30-day primary
patency rate). It would have been expected that the short-
term outcomes would be equivalent between both groups,
especially if endovascular techniques are to be considered a
viable alternative to surgical thrombectomy. Possible rea-
sons for this include the novelty of some of the endovascu-
lar techniques and a lack of experience with some of the
techniques.
In addition to the early success (at 30 days), we also
considered the longer term outcomes at 1 year to be
important. The use of a patent and functional graft to
minimize the morbidity associated with hemodialysis is
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clearly important to the patient on dialysis. The viewpoint
of proponents of noninvasive techniques is the decreased
morbidity associated with endovascular techniques. It has
been thought that if repeat thrombosis occurs, then the
endovascular techniques can be easily repeated with mini-
mal morbidity. However, one must counterbalance the
morbidity of one surgical procedure with the morbidity of
multiple endovascular procedures. The results of this study,
which indicate a significant increase in patency at 30, 60,
and 90 days and 1 year, would suggest that surgical throm-
bectomy is a more reliable approach. This result was also
reflected in the sensitivity analyses that were performed
(Tables I and II). One durable procedure does not only
decrease the morbidity associated with repeat procedures
but will alleviate the inconvenience and costs to the patient
that are associated with repeat procedures.
One downside of this metaanalysis was the need to
combine all noninvasive techniques under the umbrella of
endovascular procedures. This was done because of the
variability of the endovascular protocols. Ideally, if there
were larger numbers of studies for each method, subgroup
analyses could have been performed to determine whether
there was indeed a relatively better endovascular procedure.
Furthermore, most included studies3,10,13,14 used uroki-
nase, a product that has limited or no availability.
Several possible explanations exist for the differences
between surgical and endovascular procedures in terms of
technical failure rates. First, the endovascular approach may
be a technically more difficult procedure. As such, there
may be a learning curve that must be overcome by the
practitioner before technical expertise is achieved with the
newer endovascular techniques. Second, endovascular
techniques become technically more difficult when com-
plex anatomy is encountered. Therefore, in those patients
with difficult fistula anatomy, the likelihood of technical
failure may be increased to a greater degree with an endo-
vascular approach than with a surgical approach. Both of
these problems would result in larger rates of technical
Fig 1. Metaanalysis of aggregated data. Primary patency rates of surgical thrombectomy versus endovascular throm-
bectomy at 30 days, 60 days, 90 days, and 1 year, represented as RR.
JOURNAL OF VASCULAR SURGERY
November 2002942 Green, Lee, and Kucey
failure with endovascular procedures than with surgical
procedures. Furthermore, it may simply be because of the
inadequacy of the treatment as a whole.
A common problem encountered throughout this sys-
tematic review was a lack of proper reporting of study meth-
odology for the assessment of the quality of studies. This may
in large part be due to the lack of blinding to both intervention
and outcome, which is inevitable in surgical trials. However,
the overall strengths of all studies could be greatly improved
by paying closer attention to study design in terms of patient
allocation and randomization techniques.
A greater robustness of results would have been ob-
tained if standardized reporting methods were adopted. A
large amount of error in the results is inherent when one is
forced to extrapolate results from Kaplan-Meier survival
curves. Furthermore, primary patency rate as reported by
Marston et al,10 where it is treated as a continuous variable,
would be preferable to the artificial creation of a dichoto-
mous outcome. However, even with these minor criticisms,
the strength of the results clearly shows a significant de-
crease in technical failure rates and an increase of primary
patency rate at 30, 60, and 90 days and 1 year with surgical
thrombectomy as compared with endovascular procedures.
The analysis of all currently available randomized con-
trolled trials clearly supports the use of surgical thrombec-
tomy for the treatment of thrombosed vascular access
grafts. This procedure can be done with general, regional,
or local anesthesia as per physician and patient preferences.
The use of endovascular techniques was found to be inad-
equate in terms of both primary patency and technical
failure rates.
For endovascular techniques to be considered as a
viable alternative, improvements must be made in several
categories. First, the rate of technical failures must be
reduced to a level equal to or superior to that for surgical
thrombectomy. Second, primary patency results must also
be increased to a level comparable with that of surgical
thrombectomy. The decrease in morbidity rate associated
with endovascular techniques does not yet make it an
attractive alternative to surgical thrombectomy. Where the
Fig 2. Metaanalysis of aggregated data. Primary patency rates of surgical thrombectomy versus endovascular throm-
bectomy at 30 days, 60 days, 90 days, and 1 year, represented as RD.
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balance between a decrease in morbidity and a decrease in
patency lies, both in terms of patient preference and an
acceptable standard of care, is unclear.
Because of the small sample size in most studies, further
research is still necessary to definitively answer the study
question. A prospective multicenter randomized control
trial of surgical thrombectomy versus endovascular proce-
dures is still necessary. It is recommended that this study
focus on several key issues. First, blinding of patient alloca-
tion to the two study groups is essential. Second, a stan-
dardization of reporting guidelines should be adopted to
minimize differences in the presentation of results and the
definitions of outcome variables. Furthermore, it is be-
lieved that primary patency should be reported as a contin-
uous variable with the corresponding standard error on a
monthly basis for a minimum of 1 year after thrombec-
tomy. Third, a sample size large enough to ensure the
ability of investigators to perform subgroup analysis on the
basis of vascular access type (AVF versus PAVG) and endo-
vascular procedures (mechanical thrombectomy versus
pharmacomechanical thrombolysis versus endovascular
thrombectomy) should be used. The inclusion of AVFs in
future studies will be important as they become an increas-
ingly popular technique in the construction of AVGs. One
inevitable criticism of this systematic review will be that all
noninvasive procedures were combined together even
though all endovascular techniques may not be equal. An
answer to such a criticism will only be possible if a large
sample size is obtained and subgroup analyses can be per-
formed. Fourth, the use of urokinase as a thrombolysis
medication should be excluded until such time as the
present problems concerning availability are answered.
New endovascular techniques described for the treat-
ment of the thrombosed vascular access should be com-
pared with surgical thrombectomy as a control arm and not
against other endovascular procedures. On the basis of the
Fig 3. Metaanalysis of aggregated data. Technical failure rates of surgical thrombectomy versus endovascular
thrombectomy at 30 days, 60 days, 90 days, and 1 year, represented as both RR and RD.
Table I. Sensitivity analysis of 30-day primary patency
Study removed RR 95% CI Heterogeneity Overall effect
Martson et al10 1.26 0.99-1.59 0.35 .06
Uflacker et al15 1.24 1.01-1.53 0.67 .04
Vesely et al14 1.31 1.06-1.61 0.27 .01
Veseley et al11 1.53 1.08-2.16 0.58 .02
Heterogeneity is test for heterogeneity with 2 P value. Overall effect is
P value.
Table II. Sensitivity analysis of 1-year primary patency
Study removed RR 95% CI Heterogeneity Overall effect
Brooks et al12 1.19 1.04-1.36 1 .009
Dougherty et al3 1.24 1.05-1.46 0.46 .01
Marston et al10 1.26 1.02-1.55 0.49 .03
Heterogeneity is test for heterogeneity with 2 P value. Overall effect is P
value.
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available studies to date, we conclude that surgical throm-
bectomy should be viewed as the gold standard for the
treatment of the thrombosed vascular access. A cost analysis
between surgical thrombectomy and the various endovas-
cular techniques would also be of benefit. The final ques-
tion that must be answered is whether vascular surgeons
have the time or resources available to perform large num-
bers of surgical thrombectomies and graft revisions. These
are procedures that must be performed in a timely manner
after thrombosis to maintain the highest standard of care
for the patients on dialysis. For this reason, we still believe
that endovascular procedures will play an important role in
the treatment of thrombosed AVGs.
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